Major Growth Driver Identified in 2025 Neurological Biomarkers Market: Rising Prevalence Of Neurological Diseases Fuels Momentum In Neurological Biomarker Market

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Neurological Biomarkers Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size of neurological biomarkers has seen a swift augmentation in the past few years. Projected to escalate from $10.7 billion in 2024 to $11.96 billion in 2025, it holds a compound annual growth rate (CAGR) of 11.7%. The significant growth witnessed in the historic period can be credited to the escalating prevalence of neurological disorders, the aging populace, pharmaceutical development necessities, augmented finance for neurological studies, and customized medication.

Neurological Biomarkers Market Size Forecast: What's the Projected Valuation by 2029?
In the coming years, the size of the neurological biomarkers market is projected to experience swift expansion. By 2029, it is predicted to increase to a value of $19.96 billion, growing at a compound annual growth rate (CAGR) of 13.7%. The anticipated growth during the forecast period can be linked to the availability of biomarkers for early detection, biosensors, wearable technology, public health initiatives, and a focus on patient-specific treatment methods. Key trends during this period will include technological innovations in imaging, fast-tracked developments in omics technologies, the incorporation of artificial intelligence (AI), the use of real-world evidence in biomarker validation, progress in diagnostic technologies, and partnerships between industrial entities and research institutions.

View the full report here:
https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report

What Are the Drivers Transforming the Neurological Biomarkers Market?
The growth of the neurological biomarker market is likely to be fuelled by the escalating prevalence of neurological disorders. These disorders, impacting the brain, spinal cord, and all other nerves of the body, comprise neurodegenerative conditions like Parkinson's disease, which affects the neurological system and the body areas under nerve control. Neurological biomarkers facilitate the earlier detection of Parkinson's disease via genetic, pathological, and biochemical tests. For instance, the Parkinson's Foundation, a non-profit organization based in the US, reported a hike in new Parkinson's disease diagnoses in December 2022, with the number increasing to 90,000 from the previous year's 60,000. Hence, the surging prevalence of neurological diseases is fuelling the expansion of the neurological biomarker market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12677&type=smp

What Long-Term Trends Will Define the Future of the Neurological Biomarkers Market?
Main companies in the neurological biomarkers market are teaming up to create novel products and consolidate their marketplace standing. These partnerships facilitate innovation within the industry, tap into mutually beneficial expertise, and speed up the progression and marketing of advanced treatments through the pooling of resources and abilities. For example, in July 2022, NeuroSense Therapeutics Ltd., an organization based in Israel specializing in therapeutic solutions for critically degenerative neurological conditions, joined forces with NeuraLight, another Israel-based firm with a focus on accurate and sensitive neurological disorder biomarkers. The goal of this union is to determine oculometric indicators useful in diagnosing Amyotrophic Lateral Sclerosis (ALS), leveraging Artificial Intelligence (AI), and Machine Learning (ML). The partnership, following NeuraLight's $25 million Series A funding round, aims to expedite the identification and utilization of digital markers for ALS in parallel research, marking the duo's inaugural clinical trial. The collaboration is pivoted on the use of oculometric digital indicators, potentially leading to efficient patient categorization and enhancing the prospect of successful clinical trials.

Which Segments in the Neurological Biomarkers Market Offer the Most Profit Potential?
The neurological biomarkers market covered in this report is segmented -

1) By Product: Proteomics Biomarker, Genomics Biomarker, Metabolomics Biomarker, Imaging Biomarker, Other Products
2) By Application: Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Schizophrenia, Depression, Multiple Sclerosis, Spinal Muscular Atrophy
3) By End-User: Hospital Laboratories, Clinical Diagnostic Centers, Research Organizations, Other End-Users

Subsegments:
1) By Proteomics Biomarker: Protein Biomarkers, Antibody Biomarkers
2) By Genomics Biomarker: DNA Biomarkers, RNA Biomarkers
3) By Metabolomics Biomarker: Metabolite Biomarkers, Lipid Biomarkers
4) By Imaging Biomarker: MRI Biomarkers, PET Scan Biomarkers
5) By Other Products: Neuroinflammatory Biomarkers, Neurotransmitter Biomarkers

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12677&type=smp

Which Firms Dominate the Neurological Biomarkers Market by Market Share and Revenue in 2025?
Major companies operating in the neurological biomarkers market include Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Thermos Fisher Scientific Inc., AstraZeneca Plc, Abbott Laboratories, Boehringer Ingelheim International GmbH, Becton Dickinson and Company, Agilent Technologies Inc., Grifols S.A., Eisai Co. Ltd., PerkinElmer Inc., Illumina Inc., Shimadzu Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Mallinckrodt Plc, Qiagen N.V., Luminex Corporation, Siemens Healthineers, Olink Proteomics, Meso Scale Diagnostics, Quanterix Corp., Fujirebio, Cisbio Bioassays SAS, NeuroVision Imaging, Proteome Sciences Plc, Acumen Pharmaceuticals.

Which Regions Offer the Highest Growth Potential in the Neurological Biomarkers Market?
North America was the largest region in the neurological biomarkers market in 2024. The regions covered in the neurological biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12677

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.